NASDAQ · Biotechnology

Genenta Science S.p.A. (GNTA) Stock

$1.50 -5.66% NASDAQ: GNTA Healthcare

Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors.

Valuation

MetricValue
Price$1.50
Market Cap$28.72M
P/E Ratio-3.98
P/B Ratio1.28
P/S Ratio0.00
EPS (TTM)$-0.33
52-Week High$10.00
52-Week Low$0.55
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-36.82%
ROA-19.60%
ROCE-21.33%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.35
Current Ratio14.16

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-6.0M$-11.0M$-12.0M$-10.0M$-6.0M
Net Profit$-6.0M$-8.0M$-11.0M$-9.0M$-6.0M
EPS$-0.31$-0.47$-0.64$-0.49$-0.33
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$40.0M$33.0M$22.0M$15.0M$32.0M
Total Liabilities$1.0M$2.0M$2.0M$2.0M$10.0M
Cash$37.0M$30.0M$4.0M$5.0M$6.0M
Borrowings$0$0$0$0$8.0M

Latest News

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results GlobeNewswire · Jul 22, 2026 European Equities Traded in the US as American Depositary Receipts Decline Friday MT Newswires · Jul 17, 2026 Top Premarket Gainers MT Newswires · Jun 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-7.0M$-11.0M$-6.0M$-7.0M
Investing Cash Flow$0$0$-15.0M$7.0M$-15.0M
Financing Cash Flow$0$0$0$0$15.0M
Net Cash Flow$22.0M$-7.0M$-26.0M$1.0M$1.0M
Free Cash Flow$-7.0M$-7.0M$-11.0M$-6.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.11
EV / EBITDA-4.65
FCF Yield-30.70%
Quick Ratio14.16
Interest Coverage-17.01
Return 1Y-61.73%
Return 3Y-75.51%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
CVM $1.18 +0.00% -0.23 $8.11M 0.00%
INMB $1.73 +6.79% -2.44 $45.99M 0.00%
IPSC $2.02 -1.46% -5.04 $174.87M 0.00%
JUNSJupiter Neurosciences, Inc. $0.11 -5.37% -0.45 $4.16M 0.00%

About Genenta Science S.p.A.

Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.

Genenta Science S.p.A. is headquartered in IT.

Genenta Science S.p.A. (GNTA) stock trades at $1.50 with a market capitalization of $28.72M. The stock is valued at a price-to-earnings (P/E) ratio of -3.98, price-to-book of 1.28, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.55 and $10.00, and currently trades 85.0% below its 52-week high.

On profitability, Genenta Science S.p.A. generates a return on equity (ROE) of -36.82%, return on capital employed of -21.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.genenta.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides